Lytix Biopharma AS has received a “Notice of Allowance” from the US Patent Office regarding its LTX-315 patent application. From December 14, Lytix Biopharma’s first-in class oncolytic peptide immunotherapy LTX-315 is patent protected in the US.
LTX-315 has already been granted patent protection in Australia, New Zealand, China, South Korea and Russia
- This patent is a major milestone for the development of our first-in–class oncolytic peptide immunotherapy LTX-315. To be granted US patent is important as it represents the largest market in the world for pharmaceuticals, says Lytix Biopharma CEO Unni Hjelmaas.
- Patent protection is a cornerstone for pharmaceutical development and commercialization. Lytix Biopharma employs an advanced intellectual property strategy delivering a solid patent position for its technology. LTX-315 has patent protection until 2035, says John Sigurd Svendsen, Co-founder and Head of Exploratory Research.
LTX-315 induces a potent stimulation of an extended range of tumor-specific T-cells attacking cancer, thereby increasing patient specific immune response. LTX-315 “pushes the accelerator” of the immune system through the release of potent immune stimulants. Furthermore, LTX-315 differentiates from many other cancer immunotherapies by inducing the release of an extended range of patient-specific tumor antigens including neo-antigens.
Combinations of complementary immunotherapy treatments are expected to be an integral part of future cancer treatment delivering significant clinical benefit. ICIs “release the brakes” imposed by the tumor on the immune system. LTX-315 has the potential to augment efficacy of ICIs without adding toxicity.